WO2019189992A1 - Composition for preventing, alleviating or treating inflammatory diseases, containing zanthoxylum schinifolium oil as active ingredient - Google Patents
Composition for preventing, alleviating or treating inflammatory diseases, containing zanthoxylum schinifolium oil as active ingredient Download PDFInfo
- Publication number
- WO2019189992A1 WO2019189992A1 PCT/KR2018/005432 KR2018005432W WO2019189992A1 WO 2019189992 A1 WO2019189992 A1 WO 2019189992A1 KR 2018005432 W KR2018005432 W KR 2018005432W WO 2019189992 A1 WO2019189992 A1 WO 2019189992A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disease
- inflammatory
- active ingredient
- composition
- inflammatory diseases
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 20
- 239000004480 active ingredient Substances 0.000 title claims abstract description 18
- 241001079064 Zanthoxylum schinifolium Species 0.000 title abstract 3
- 208000006673 asthma Diseases 0.000 claims description 33
- 210000003022 colostrum Anatomy 0.000 claims description 30
- 235000021277 colostrum Nutrition 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 12
- 206010020751 Hypersensitivity Diseases 0.000 claims description 11
- 208000026935 allergic disease Diseases 0.000 claims description 11
- 235000013376 functional food Nutrition 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 8
- 201000008937 atopic dermatitis Diseases 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- -1 foundation Substances 0.000 claims description 7
- 230000006872 improvement Effects 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 201000008383 nephritis Diseases 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 206010069002 Autoimmune pancreatitis Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 206010010741 Conjunctivitis Diseases 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 208000004145 Endometritis Diseases 0.000 claims description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 3
- 206010068319 Oropharyngeal pain Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 206010033078 Otitis media Diseases 0.000 claims description 3
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims description 3
- 201000007100 Pharyngitis Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010038910 Retinitis Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 230000036783 anaphylactic response Effects 0.000 claims description 3
- 208000003455 anaphylaxis Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 3
- 208000013507 chronic prostatitis Diseases 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 201000003146 cystitis Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 208000024908 graft versus host disease Diseases 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 208000028169 periodontal disease Diseases 0.000 claims description 3
- 201000007094 prostatitis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 206010039083 rhinitis Diseases 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 206010044008 tonsillitis Diseases 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 abstract description 15
- 102000004127 Cytokines Human genes 0.000 abstract description 15
- 230000002757 inflammatory effect Effects 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 241000196324 Embryophyta Species 0.000 abstract 2
- 238000000605 extraction Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 14
- 108010058846 Ovalbumin Proteins 0.000 description 11
- 210000004969 inflammatory cell Anatomy 0.000 description 11
- 229940092253 ovalbumin Drugs 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 10
- 238000010171 animal model Methods 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 230000002378 acidificating effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000009610 hypersensitivity Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000007906 compression Methods 0.000 description 7
- 230000006835 compression Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000012530 fluid Substances 0.000 description 6
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 5
- 229960002329 methacholine Drugs 0.000 description 5
- 238000003825 pressing Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010000269 abscess Diseases 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000002417 nutraceutical Substances 0.000 description 3
- 235000021436 nutraceutical agent Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
- 239000000052 vinegar Substances 0.000 description 3
- 235000021419 vinegar Nutrition 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000010085 airway hyperresponsiveness Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 229960004784 allergens Drugs 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229930007050 cineol Natural products 0.000 description 2
- 229960005233 cineole Drugs 0.000 description 2
- NEHNMFOYXAPHSD-UHFFFAOYSA-N citronellal Chemical compound O=CCC(C)CCC=C(C)C NEHNMFOYXAPHSD-UHFFFAOYSA-N 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000001422 normality test Methods 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- LFJQCDVYDGGFCH-JTQLQIEISA-N (+)-β-phellandrene Chemical compound CC(C)[C@@H]1CCC(=C)C=C1 LFJQCDVYDGGFCH-JTQLQIEISA-N 0.000 description 1
- LFJQCDVYDGGFCH-SNVBAGLBSA-N (+/-)-beta-Phellandrene Natural products CC(C)[C@H]1CCC(=C)C=C1 LFJQCDVYDGGFCH-SNVBAGLBSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 244000207543 Euphorbia heterophylla Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000238711 Pyroglyphidae Species 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 208000024716 acute asthma Diseases 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 230000008371 airway function Effects 0.000 description 1
- 230000008369 airway response Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- LFJQCDVYDGGFCH-UHFFFAOYSA-N beta-phellandrene Natural products CC(C)C1CCC(=C)C=C1 LFJQCDVYDGGFCH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 235000000983 citronellal Nutrition 0.000 description 1
- 229930003633 citronellal Natural products 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000003898 horticulture Methods 0.000 description 1
- 229940046533 house dust mites Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 108010029307 thymic stromal lymphopoietin Proteins 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Definitions
- the present invention relates to a composition for preventing, ameliorating or treating an inflammatory disease comprising an acidic colostrum as an active ingredient.
- Inflammation refers to the pathological condition of an abscess formed by the invasion of external infectious agents (bacteria, fungi, viruses, various types of allergens). Specifically, when the external bacteria invade specific tissues and proliferate, the white blood cells of the living body recognize this, and actively attack the multiplying external bacteria. The dead sea of white blood cells generated during this process accumulates in the tissues invaded by the bacteria. At the same time, cell destruction of invading bacteria killed by leukocytes is fused into the invaded tissue, forming an abscess. Inflammation of the abscess may be promoted through anti-inflammatory action.
- infectious agents bacteria, fungi, viruses, various types of allergens
- Anti-inflammatory action is to use an antibacterial agent to inhibit the growth of invading bacteria or to activate macrophages that feed on the foreign substances accumulated in the abscess to digest the foreign substances. And promotes inflammation, such as promoting the function of the macrophages to excrete.
- an inflammatory reaction is a biodefense reaction process for repairing and regenerating damage caused by an invasion that causes organic changes in cells or tissues of the living body, and this reaction process includes local blood vessels, various tissue cells of body fluids and immune cells
- This works Normally, the inflammatory response induced by external invading bacteria is a defense system for protecting the living body, whereas abnormally excessive inflammatory response is induced, and various diseases appear. These diseases are called inflammatory diseases.
- the inflammatory disease is a disease that threatens human life by amplifying and sustaining inflammation of various inflammatory mediators secreted from target cells activated by external stimuli.
- Inflammatory diseases caused by such inflammation include asthma, chronic obstructive pulmonary disease, allergies, systemic lupus erythematosus, scleroderma, ulcerative colitis, Crohn's disease, atopic dermatitis, psoriasis, anaphylaxis, dermatitis, diabetic retinopathy, retinitis, macular Degeneration, uveitis, conjunctivitis, arthritis, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, osteoporosis, diabetes, diabetic nephropathy, nephritis, nephritis, Sjogren's syndrome, Crohn's disease, autoimmune pancreatitis, periodontal disease, graft-versus-host disease, chronic pelvic inflammation Diseases, endometritis, rhinitis, tonsillitis, otitis media, sore throat, cystitis and chronic prostatitis.
- asthma is an important health problem with more than 300 million patients worldwide.
- the burden of chronic disease is the sixth largest disease.
- the prevalence of asthma is still increasing in many countries.
- asthma is slowing down as the prevalence of rapid prevalence declined, but adult asthma continues to increase, which is why social asthma is a greater social burden in Korea. This suggests the possibility of coming.
- Asthma is one of the most common chronic airway diseases, characterized by symptoms such as shortness of breath, wheezing, tightness of the chest, and coughing along with reversible exhalation of airflow. Asthma is a combination of genetic and environmental factors. Environmental factors include house dust mites and pollen-causing agents and colds, smoking, air pollution and yellow dust. Asthma, which is known to be difficult to cure, appears repeatedly and seizure, so ongoing management is an important disease. These asthma vary depending on the season or worsening factors, such as exercise, allergens (antigens) or irritants, weather changes, respiratory viral infections such as cold. Acute asthma exacerbations can be life threatening.
- Asthma is most often associated with airway hyperresponsiveness to direct or indirect stimuli or chronic inflammation of the airways and has similar clinical manifestations, but is a non-uniform disease with a combination of different pathophysiology. Most medicines reduce the number of remissions and manifestations, and therefore, there is an urgent need to develop treatments for asthma.
- Japanese vinegar belongs to Unhyang family, and essential oils extracted from fruits are mainly used for food and medicine.
- the vinegar contains limonine (Limonene (58%), citronellal (22%), beta-ferrandene ( ⁇ -Phellandrene (6.4%)), cineol (Cineol, 2.2%), dipentene (Dipentene, 1.2%) and other essential oils.
- Most of the colostrums are 30 kinds of fatty acids, which are divided into saturated fatty acids and unsaturated fatty acids. Among them, unsaturated fatty acids are composed of monounsaturated fatty acids and polyunsaturated fatty acids.
- the acidic oil contains 45% or more of polyunsaturated fatty acids linoleic acid and linolenic acid, which are carriers of fat-soluble vitamins A, D, E, and K, and are known to play an essential fatty acid role in the body after taking.
- Korean Patent Publication No. 2017-0091804 discloses a composition for preventing, ameliorating or treating an allergic disease
- Korean Patent Publication No. 2017-0132394 is isolated from cholinine or pharmaceuticals thereof
- An anti-tuberculosis pharmaceutical composition containing an acceptable salt thereof and a method for preparing the same are disclosed, but there is no disclosure about a composition for preventing, ameliorating or treating an inflammatory disease including the acidic colostrum of the present invention as an active ingredient.
- the present invention is derived from the above requirements, the present invention provides a composition for the prevention, improvement or treatment of inflammatory diseases comprising an acidic colostrum as an active ingredient, the sancho of Xperla milked Hancho variety according to the present invention
- the present invention was completed by significantly reducing the expression of inflammatory cytokines in milk and confirming a decrease in the number of inflammatory cells in bronchial alveolar lavage, a decrease in airway hyperresponsiveness and morphological changes in lung tissue in an asthma-induced animal model. .
- the present invention provides a health functional food composition for the prevention or improvement of inflammatory diseases containing acid colostrum milked with the Expela method as an active ingredient.
- the present invention also provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases containing acid colostrum milked by the Expela method as an active ingredient.
- the present invention also provides a quasi-drug for improving asthma or atopic dermatitis, which contains acid colostrum milked by the Expela method as an active ingredient.
- the present invention relates to a composition for preventing, ameliorating or treating an inflammatory disease comprising an acidic colostrum as an active ingredient, wherein the anhydrous colostrum of the Xpella milked Hancho variety according to the present invention significantly reduces the expression of inflammatory cytokines, and asthma.
- bronchoalveolar lavage fluid reduces the number of inflammatory cells and reduces airway hypersensitivity, and has the effect of inducing morphological changes of lung tissue.
- Figure 1 shows the change in the expression level of inflammatory cytokines (IL-25) in A549 cells treated with varietal colostrum by varieties and milking methods.
- A is an early species
- B is an endemic species
- C is an herbaceous variety of the herbaceous variety.
- Samples 1, 4 and 7 were milked by hydraulic compression, containing 10% shell
- Samples 2, 5, and 8 were milked by hydraulic pressing, without shells
- Samples 3, 6, and 9 were milked with Xpella and did not contain shells.
- Figure 2 shows the change in the expression level of inflammatory cytokines (IL-33) in A549 cells treated with varietal colostrum by varieties and milking methods.
- A is an early species
- B is an endemic species
- C is an herbaceous variety of the herbaceous variety.
- Samples 1, 4 and 7 were milked by hydraulic compression, containing 10% shell
- Samples 2, 5, and 8 were milked by hydraulic pressing, without shells
- Samples 3, 6, and 9 were milked with Xpella and did not contain shells.
- Figure 3 shows the change in the expression level of inflammatory cytokines (IL-5) in A549 cells treated with varietal colostrum by varieties and milking methods.
- A is an early species
- B is an endemic species
- C is an herbaceous variety of the herbaceous variety.
- Samples 1, 4 and 7 were milked by hydraulic compression, containing 10% shell
- Samples 2, 5, and 8 were milked by hydraulic pressing, without shells
- Samples 3, 6, and 9 were milked with Xpella and did not contain shells.
- Figure 4 shows the change in the expression level of inflammatory cytokines (TSLP; thymic stromal lymphopoietin) in A549 cells treated with varieties and milking method.
- TSLP inflammatory cytokines
- (A) is an early species
- (B) is an endemic species
- (C) is an herbaceous variety of the herbaceous variety.
- Samples 1, 4 and 7 were milked by hydraulic compression, containing 10% shell
- Samples 2, 5, and 8 were milked by hydraulic pressing, without shells
- Samples 3, 6, and 9 were milked with Xpella and did not contain shells.
- Figure 5 shows the changes in the expression level of inflammatory cytokines (IL-25, IL-33, IL-5, TSLP) in primary tracheal epithelial cells treated with acetic acid of Hancho variety by milking method will be.
- Sample 7 was milked by hydraulic compression, containing 10% shell;
- Sample 8 was milked by hydraulic pressing, without shells;
- Sample 9 was milked with xpella and does not contain shells.
- FIG. 6 shows a protocol for establishing an asthma-induced animal model and confirming the efficacy of colostrum according to the present invention.
- Figure 7 is a result of analyzing the inflammatory cells in the bronchial alveolar lavage fluid (BAL fluids) of the asthma-induced animal model to which the acetic acid of the herb varieties according to the present invention.
- IL-4 and IL-13 are cytokines (IL-4 and IL-13) in the lung tissue of an asthma-derived animal model to which the herbal herb of the herb varieties according to the present invention was administered.
- FIG. 10 is a result of morphological analysis of lung tissue of an asthma-induced animal model to which the acetic acid of Hancho variety according to the present invention was administered.
- the present invention relates to a nutraceutical composition for the prevention or improvement of inflammatory diseases containing acid colostrum milked by the Expela method as an active ingredient.
- the sancho oil is characterized in that the varieties of hancho varieties, and preferably at least one selected from No. 10, No. 5, No. 15 and No. 930, but not limited thereto.
- the inflammatory disease is a disease caused by increased cytokine secretion causing an inflammatory response, specifically, asthma, bronchitis, chronic obstructive pulmonary disease, atopic dermatitis, allergy, systemic lupus erythematosus, scleroderma, ulcerative colitis, Crohn Disease, psoriasis, anaphylaxis, dermatitis, diabetic retinopathy, retinitis, macular degeneration, uveitis, conjunctivitis, arthritis, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, osteoporosis, diabetes, diabetic nephropathy, nephritis, nephritis, Sjogren's syndrome, Crohn's disease, Autoimmune pancreatitis, periodontal disease, graft-versus-host disease, chronic pelvic inflammatory disease, endometritis, rhinitis, tonsillitis
- the dietary supplement composition of the present invention may be prepared in any one formulation selected from powders, granules, pills, tablets, capsules, candy, syrups and beverages, but is not limited thereto.
- the health functional food composition of the present invention When used as a food additive, the health functional food composition may be added as it is or used with other foods or food ingredients, and may be appropriately used according to a conventional method.
- the active ingredient may be appropriately used depending on the purpose of use (prevention or improvement).
- the nutraceutical composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less based on the raw materials.
- the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.
- dietary supplement there is no particular limitation on the type of dietary supplement.
- foods to which the health functional food composition may be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products, including ice cream, various soups, drinks, tea Drinks, alcoholic beverages, vitamin complexes, and the like, and include all health foods in the conventional sense.
- the nutraceutical composition of the present invention may be prepared as a food, in particular a functional food.
- the functional food of the present invention may include ingredients that are commonly added. Examples include proteins, carbohydrates, fats, nutrients and seasonings.
- natural carbohydrates or flavors may be included as additional ingredients in addition to the active ingredient.
- the natural carbohydrates can be monosaccharides (e.g. glucose, fructose, etc.), disaccharides (e.g. maltose, sucrose, etc.), oligosaccharides, polysaccharides (e.g. dextrins, cyclodextrins, etc.) or sugar alcohols (e.g.
- the flavourant may be a natural flavourant (eg, taumartin, stevia extract, etc.) and a synthetic flavourant (eg, saccharin, aspartame, etc.).
- the carbonation agent etc. which are used for a drink can be contained further.
- the ratio of the above-mentioned ingredients is not critical, it is generally selected from 0.01 to 0.1 parts by weight based on 100 parts by weight of the health functional food composition of the present invention.
- the present invention also relates to a pharmaceutical composition for the prevention or treatment of inflammatory diseases containing acid colostrum milked by the Expela method as an active ingredient.
- the sancho oil is characterized in that the varieties of hancho varieties, and preferably at least one selected from No. 10, No. 5, No. 15 and No. 930, but not limited thereto.
- the pharmaceutical composition comprising the acidic colostrum according to the present invention is preferably a formulation of a cream, gel, patch, spray, ointment, warning, lotion, linen, pasta or cataplasma, but is not limited thereto.
- a carrier, excipient or diluent, which may be included in the pharmaceutical composition including acid colostrum, may further include a pharmaceutically acceptable carrier, excipient or diluent in addition to the acid colostrum, and lactose, dextrose, sucrose, oligosaccharide, Sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydride Oxybenzoate, talc, magnesium stearate and mineral oil. When formulated, it may be prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc. which are commonly used.
- Preferred dosages of the colostrum of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art.
- the pharmaceutical composition containing the acidic oil of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably 0.001 to 10 mg / kg per day. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
- the present invention also relates to quasi-drugs for improving asthma or atopic dermatitis containing acid colostrum milked by the Expela method as an active ingredient.
- the quasi-drug is prepared in any one formulation selected from solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsions, foundations, wax foundations and sprays. It is preferable, but it is not limited to this.
- the three cultivars of crude, late and varieties of horticulture, inflammatory cytokines (IL-25, IL-33, against the samples for nine cases obtained through hydraulic compression or expeller milking) IL-5 and TSLP) expression level changes were analyzed.
- the herbaceous cultivars milked with the Expel milking method of the present invention were orally administered to an OVA (ovalbumin) -induced asthma mouse model, and the number of inflammatory cells, expression of proteins involved in inflammation, and airway hypersensitivity. And histological analysis.
- OVA ovalbumin
- the raw colostrum was added corn oil (drug vehicle), and the crude colostrum was diluted to 0.2% and 2% of each sample. Corn oil and colostrum were orally administered 1 hour before the last 3% OVA challenge and 6 hours after the last 3% OVA challenge.
- mice were sacrificed at 48 hours after the last OVA challenge.
- the mouse model group was classified into the negative control group (SAL + VEH), the oVA group treated with ovalbumin, and the ovalbumin-treated and acid colostrum (0.2 or 2% per second) (FIG. 6).
- mice were sacrificed by cervical dislocation, 1 ml of PBS was added to the trachea to wash the lungs, and bronchial alveolar lavage fluid was obtained. Total cell number was measured using NucleoCounter (ChemoMetec, Allerod, Denmark), and BAL cell smears were prepared with cytospin (Thermo Eletronm Waltham, Mass.). For cell differentiation, after staining with Diff-Quik solution (Dade diagnostics of P.R. Inc.Aguada, Puerto Rico), 400 cells were counted and analyzed, and samples showing efficacy in inflammatory cell analysis were selected.
- Diff-Quik solution Diff-Quik solution
- the total cell number, inflammatory cells including eosinophil and lymphocytes were significantly increased in the asthma model, and the total cell number and eosinophil in the experimental group administered 2% per second. It was confirmed that the cell number of was reduced.
- Mouse lung tissue of the sample selected in the inflammatory cell analysis was homogenized with lysis buffer to obtain protein lysates of lung tissue. Proteins were quantified by the Bradford technique, followed by electrophoresis, membrane transfer, and blocking to incubate IL-4 and IL-13 antibodies overnight. The next day the blots were washed, the secondary antibodies reacted, the ECL reactions were analyzed and analyzed using the LAS instrument.
- IL-4 and IL-13 proteins were increased in lung tissue of the asthma model. It was confirmed that the increased IL-4 and IL-13 protein was decreased in the animal model administered with the acetic acid of Hancho variety of the present invention (Fig. 8).
- asthma model group showed increased airway hypersensitivity in a dose-dependent manner compared to negative control group (SAL + VEH), and increased airway hypersensitivity was decreased in the experimental group administered 2% per second. It was confirmed (FIG. 9).
- lung tissue was removed from mice 48 hours after the last OVA challenge and fixed in 4% formalin. Samples were dehydrated and fixed with paraffin and attached to slides in 4 ⁇ m sections with a Leica model 2165 rotary microtome (Leica Microsystems Nussloch GmbH, Nussloch, Germany). The tissues were then deparaffinized and hydrolyzed and H & E stained. Histologically, the inflammatory scores were analyzed to evaluate lung inflammation.
- the pathological examination of the asthma model showed a thickening of the epithelial cell layer, a significant increase in inflammatory cell infiltration around the bronchus and blood vessels, and significantly improved pathological changes in the experimental group treated with 2% per second. It could be observed (Fig. 10).
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a composition for preventing, alleviating or treating inflammatory diseases, containing Zanthoxylum schinifolium oil as an active ingredient. Specifically, it has been ascertained that Zanthoxylum schinifolium oil, extracted by an expeller type oil extraction method, has an effect of reducing the expression of inflammatory cytokines and, particularly, among various varieties (early-maturing variety, late-maturing variety and drought-resistant plants), a drought-resistant plant variety has a remarkable anti-inflammatory effect.
Description
본 발명은 산초유를 유효성분으로 포함하는 염증성 질환의 예방, 개선 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing, ameliorating or treating an inflammatory disease comprising an acidic colostrum as an active ingredient.
염증(inflammation)은 외부 감염원(박테리아, 곰팡이, 바이러스, 다양한 종류의 알레르기 유발물질)의 침입에 의하여 형성되는 농양의 병리적 상태를 뜻한다. 구체적으로, 외부 세균이 특정 조직에 침입하여 증식을 하게 되면 생체의 백혈구가 이를 인지하여 증식된 외부 세균을 활발히 공격하게 되는데, 이 과정 중 발생하는 백혈구의 사해가 균에 의하여 침입받은 조직에 축적됨과 동시에 백혈구에 의하여 사멸된 침입 균의 세포 파괴물이 침입받은 조직 내로 융해되어 농양이 형성된다. 염증에 의한 농양의 치료는 소염작용을 통하여 촉진될 수 있는데, 소염작용이란 항균제를 이용하여 침입 균의 증식을 억제하거나 농양 중에 축적된 이물질들을 탐식하는 대식세포(macrophage)를 활성화하여 상기 이물질들을 소화 및 배설하는 대식세포의 기능을 항진시키는 등의 염증치료 촉진작용이다.Inflammation refers to the pathological condition of an abscess formed by the invasion of external infectious agents (bacteria, fungi, viruses, various types of allergens). Specifically, when the external bacteria invade specific tissues and proliferate, the white blood cells of the living body recognize this, and actively attack the multiplying external bacteria. The dead sea of white blood cells generated during this process accumulates in the tissues invaded by the bacteria. At the same time, cell destruction of invading bacteria killed by leukocytes is fused into the invaded tissue, forming an abscess. Inflammation of the abscess may be promoted through anti-inflammatory action. Anti-inflammatory action is to use an antibacterial agent to inhibit the growth of invading bacteria or to activate macrophages that feed on the foreign substances accumulated in the abscess to digest the foreign substances. And promotes inflammation, such as promoting the function of the macrophages to excrete.
일반적으로 염증반응은 생체의 세포나 조직에 기질적 변화를 가져오는 침습으로 인한 손상을 수복 및 재생하기 위한 생체방어 반응과정이고, 이 반응과정에는 국소의 혈관, 체액의 각종 조직세포 및 면역세포 등이 작용한다. 정상적으로 외부 침입 균에 의하여 유도되는 염증반응은 생체를 보호하기 위한 방어 시스템인 반면, 비정상적으로 과도한 염증반응이 유도되면 다양한 질환들이 나타나게 되는데, 이러한 질환들을 염증질환이라 칭한다. 상기 염증질환은 외부자극에 의하여 활성화된 표적세포로부터 분비되는 다양한 염증 매개물질이 염증을 증폭 및 지속시켜 인체의 생명을 위협하는 질환이다. 이와 같은 염증에 의해 발생하는 염증성 질환에는 천식, 만성폐쇄성폐질환, 알레르기, 전신성 홍반성 루푸스, 경피증, 궤양성 대장염, 크론병, 아토피성 피부염, 건선, 아나필락시스, 피부염, 당뇨병성 망막증, 망막염, 황반 변성, 포도막염, 결막염, 관절염, 류마티스성 관절염, 강직성 척추염, 골관절염, 골다공증, 당뇨, 당뇨성 신장병, 신염, 신장염, 쇼그렌 증후군, 크론씨 병, 자가 면역 췌장염, 치주질환, 이식편 대 숙주 질환, 만성 골반 염증 질환, 자궁내막염, 비염, 편도염, 중이염, 인후염, 방광염 및 만성 전립선염 등 다양한 질환이 포함된다. In general, an inflammatory reaction is a biodefense reaction process for repairing and regenerating damage caused by an invasion that causes organic changes in cells or tissues of the living body, and this reaction process includes local blood vessels, various tissue cells of body fluids and immune cells This works. Normally, the inflammatory response induced by external invading bacteria is a defense system for protecting the living body, whereas abnormally excessive inflammatory response is induced, and various diseases appear. These diseases are called inflammatory diseases. The inflammatory disease is a disease that threatens human life by amplifying and sustaining inflammation of various inflammatory mediators secreted from target cells activated by external stimuli. Inflammatory diseases caused by such inflammation include asthma, chronic obstructive pulmonary disease, allergies, systemic lupus erythematosus, scleroderma, ulcerative colitis, Crohn's disease, atopic dermatitis, psoriasis, anaphylaxis, dermatitis, diabetic retinopathy, retinitis, macular Degeneration, uveitis, conjunctivitis, arthritis, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, osteoporosis, diabetes, diabetic nephropathy, nephritis, nephritis, Sjogren's syndrome, Crohn's disease, autoimmune pancreatitis, periodontal disease, graft-versus-host disease, chronic pelvic inflammation Diseases, endometritis, rhinitis, tonsillitis, otitis media, sore throat, cystitis and chronic prostatitis.
한편, 염증성 질환 중에서 천식은 전 세계적으로 3억 명 이상의 환자가 있는 중요한 보건학적인 문제이며, 우리나라에서도 만성질환 중 질병부담이 6번째로 큰 질환으로 조사되었다. 천식의 유병률은 아직 많은 국가에서 지속적으로 증가하는 추세이다. 국내에서도 소아 천식은 이전에 보였던 빠른 유병률 증가가 꺾이면서 증가추세가 완화되어가고 있지만, 성인 천식은 지속적으로 증가하고 있으며, 이는 빠르게 고령화 사회에 진입하고 있는 우리나라에서 향후 천식이 지금보다도 더 큰 사회적 부담으로 다가올 가능성을 시사한다고 볼 수 있다. On the other hand, asthma is an important health problem with more than 300 million patients worldwide. In Korea, the burden of chronic disease is the sixth largest disease. The prevalence of asthma is still increasing in many countries. In Korea, asthma is slowing down as the prevalence of rapid prevalence declined, but adult asthma continues to increase, which is why social asthma is a greater social burden in Korea. This suggests the possibility of coming.
천식은 가장 흔한 만성 기도 질환 중 하나로 호흡곤란, 천명, 가슴 답답함, 기침과 같은 증상이 가역적인 호기 기류제한과 함께 나타나는 것을 특징으로 한다. 천식은 유전적 요인과 환경적 요인이 복합적으로 작용해 생긴다. 환경적 요인으로는 집먼지 진드기, 꽃가루 등 원인 물질과 감기, 흡연, 공기오염, 황사 등이 있다. 완치가 어렵다고 알려진 천식은 반복적이고 발작적으로 증세가 나타나므로 지속적인 관리가 중요한 질환이다. 이런 천식은 계절 또는 악화 인자 등에 따라 다양하게 변화하며, 천식의 악화 인자로는 운동, 알레르겐(항원) 혹은 자극성 물질, 날씨 변화, 감기 같은 호흡기 바이러스 감염 등이 있다. 천식 급성 악화는 생명을 위협할 수도 있다. 천식은 대부분 직/간접적인 자극에 대한 기도과민성이나 기도의 만성 염증과 관련이 있고, 유사한 임상양상을 보이지만, 서로 다른 병태생리가 있는 질환이 섞여 있는 균일하지 않은 질환으로, 병의 완치보다는 증상의 완화와 발현 횟수를 줄이는 약재가 대부분이며, 따라서 천식 치료제 개발이 시급하다.Asthma is one of the most common chronic airway diseases, characterized by symptoms such as shortness of breath, wheezing, tightness of the chest, and coughing along with reversible exhalation of airflow. Asthma is a combination of genetic and environmental factors. Environmental factors include house dust mites and pollen-causing agents and colds, smoking, air pollution and yellow dust. Asthma, which is known to be difficult to cure, appears repeatedly and seizure, so ongoing management is an important disease. These asthma vary depending on the season or worsening factors, such as exercise, allergens (antigens) or irritants, weather changes, respiratory viral infections such as cold. Acute asthma exacerbations can be life threatening. Asthma is most often associated with airway hyperresponsiveness to direct or indirect stimuli or chronic inflammation of the airways and has similar clinical manifestations, but is a non-uniform disease with a combination of different pathophysiology. Most medicines reduce the number of remissions and manifestations, and therefore, there is an urgent need to develop treatments for asthma.
산초나무는 운향과에 속하며 열매에서 추출한 정유물질은 주로 식·약용으로 사용하고 있다. 산초과실에는 리모닌(Limonene, 58%), 시트로네랄(Citronellal, 22%), 베타-페란드렌(β-Phellandrene, 6.4%), 시네올(Cineol, 2.2%), 디펜텐(Dipentene, 1.2%) 등의 정유물질이 함유되어 있다. 대부분의 산초유는 30여 종의 지방산으로 포화지방산과 불포화지방산으로 구분되고 있으며, 그 중 불포화지방산은 단가불포화지방산과 다가불포화지방산으로 구성되어 있다. 산초기름의 성분(수분 10.5%, 조단백 9%, 조지방 37.8%, 조섬유 14.5%, 조회분 8%, 기타 20.3%) 중에 지방함량이 약 38%로서 그 중 리놀산(Linoleic, 26%)과 리놀렌산(Linolenic, 29.2%), 오레인산(Oleic, 35%) 등 대부분의 불포화지방산으로 구성되어 있으며, 회분(8%)의 함량은 참깨(5.3%), 호두(2.3%), 은행(1.2%)보다 많이 함유하고 있다. 또한, 상온에서 항상 액체상태로 존재하므로 상시 이용할 수 있는 기능적 특성을 지니고 있다. 특히 산초기름은 지용성 비타민인 A, D, E, K 등의 운반체 역할을 하는 다가불포화지방산인 리놀산과 리놀렌산이 45% 이상 함유되어 있어 복용 후 체내에서 필수지방산 역할을 하는 것으로 알려져 있다.Japanese vinegar belongs to Unhyang family, and essential oils extracted from fruits are mainly used for food and medicine. The vinegar contains limonine (Limonene (58%), citronellal (22%), beta-ferrandene (β-Phellandrene (6.4%)), cineol (Cineol, 2.2%), dipentene (Dipentene, 1.2%) and other essential oils. Most of the colostrums are 30 kinds of fatty acids, which are divided into saturated fatty acids and unsaturated fatty acids. Among them, unsaturated fatty acids are composed of monounsaturated fatty acids and polyunsaturated fatty acids. About 38% of the components of acidic oil (moisture 10.5%, crude protein 9%, crude fat 37.8%, crude fiber 14.5%, crude ash 8%, other 20.3%) were linoleic acid (26%) and linolenic acid (26%). Linolenic (29.2%) and most unsaturated fatty acids such as oleic acid (Oleic, 35%), ash content (8%) is higher than sesame (5.3%), walnut (2.3%), ginkgo (1.2%) It contains a lot. In addition, since it is always in a liquid state at room temperature has a functional characteristic that can be used at all times. Especially, the acidic oil contains 45% or more of polyunsaturated fatty acids linoleic acid and linolenic acid, which are carriers of fat-soluble vitamins A, D, E, and K, and are known to play an essential fatty acid role in the body after taking.
산초유 관련 기술로서, 한국공개특허 제2017-0091804호에 알레르기 질환의 예방, 개선 또는 치료용 조성물에 대해 개시되어 있고, 한국공개특허 제2017-0132394호에 산초나무에서 단리한 콜리닌 또는 이의 약학적으로 허용되는 염을 함유하는 항결핵 약학 조성물 및 그 제조방법에 대해 개시되어 있으나, 본 발명의 산초유를 유효성분으로 포함하는 염증성 질환의 예방, 개선 또는 치료용 조성물에 대해서 개시된 바는 없다. As a technique related to acetic acid, Korean Patent Publication No. 2017-0091804 discloses a composition for preventing, ameliorating or treating an allergic disease, and Korean Patent Publication No. 2017-0132394 is isolated from cholinine or pharmaceuticals thereof An anti-tuberculosis pharmaceutical composition containing an acceptable salt thereof and a method for preparing the same are disclosed, but there is no disclosure about a composition for preventing, ameliorating or treating an inflammatory disease including the acidic colostrum of the present invention as an active ingredient.
본 발명은 상기와 같은 요구에 의해 도출된 것으로서, 본 발명은 산초유를 유효성분으로 포함하는 염증성 질환의 예방, 개선 또는 치료용 조성물을 제공하고, 본 발명에 따른 엑스펠라 착유된 한초 품종의 산초유가 염증성 사이토카인의 발현을 현저하게 감소시키고, 천식이 유도된 동물모델에서 기관지 폐포 세척액에서의 염증세포 수의 감소, 기도 과민성의 감소 및 폐 조직의 형태학적 변화를 확인함으로써, 본 발명을 완성하였다.The present invention is derived from the above requirements, the present invention provides a composition for the prevention, improvement or treatment of inflammatory diseases comprising an acidic colostrum as an active ingredient, the sancho of Xperla milked Hancho variety according to the present invention The present invention was completed by significantly reducing the expression of inflammatory cytokines in milk and confirming a decrease in the number of inflammatory cells in bronchial alveolar lavage, a decrease in airway hyperresponsiveness and morphological changes in lung tissue in an asthma-induced animal model. .
상기 목적을 달성하기 위하여, 본 발명은 엑스펠라(Ex pela)법으로 착유된 산초유를 유효성분으로 함유하는 염증성 질환의 예방 또는 개선용 건강기능식품 조성물을 제공한다.In order to achieve the above object, the present invention provides a health functional food composition for the prevention or improvement of inflammatory diseases containing acid colostrum milked with the Expela method as an active ingredient.
또한, 본 발명은 엑스펠라(Ex pela)법으로 착유된 산초유를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학 조성물을 제공한다.The present invention also provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases containing acid colostrum milked by the Expela method as an active ingredient.
또한, 본 발명은 엑스펠라(Ex pela)법으로 착유된 산초유를 유효성분으로 함유하는 천식 또는 아토피 피부염 개선용 의약외품을 제공한다.The present invention also provides a quasi-drug for improving asthma or atopic dermatitis, which contains acid colostrum milked by the Expela method as an active ingredient.
본 발명은 산초유를 유효성분으로 포함하는 염증성 질환의 예방, 개선 또는 치료용 조성물에 관한 것으로, 본 발명에 따른 엑스펠라 착유된 한초 품종의 산초유가 염증성 사이토카인의 발현을 현저하게 감소시키고, 천식이 유도된 동물모델에서 기관지 폐포 세척액에서의 염증세포 수의 감소 및 기도 과민성을 감소시키며, 폐 조직의 형태학적 변화를 유도하는 효과가 있는 것이다.The present invention relates to a composition for preventing, ameliorating or treating an inflammatory disease comprising an acidic colostrum as an active ingredient, wherein the anhydrous colostrum of the Xpella milked Hancho variety according to the present invention significantly reduces the expression of inflammatory cytokines, and asthma. In this induced animal model, bronchoalveolar lavage fluid reduces the number of inflammatory cells and reduces airway hypersensitivity, and has the effect of inducing morphological changes of lung tissue.
도 1은 품종 및 착유법 별 산초유를 처리한 A549 세포에서의 염증성 사이토카인(IL-25)의 발현량 변화를 확인한 것이다. (A)는 조생종이고, (B)는 만생종이며, (C)는 한초 품종의 산초이다. 시료 1, 4 및 7은 유압압착으로 착유한 것으로, 껍질이 10% 포함된 것이며; 시료 2, 5 및 8은 유압압착으로 착유한 것으로, 껍질이 포함되지 않은 것이고; 시료 3, 6 및 9는 엑스펠라 착유한 것으로, 껍질이 포함되지 않은 것이다.Figure 1 shows the change in the expression level of inflammatory cytokines (IL-25) in A549 cells treated with varietal colostrum by varieties and milking methods. (A) is an early species, (B) is an endemic species, and (C) is an herbaceous variety of the herbaceous variety. Samples 1, 4 and 7 were milked by hydraulic compression, containing 10% shell; Samples 2, 5, and 8 were milked by hydraulic pressing, without shells; Samples 3, 6, and 9 were milked with Xpella and did not contain shells.
도 2는 품종 및 착유법별 산초유를 처리한 A549 세포에서의 염증성 사이토카인(IL-33)의 발현량 변화를 확인한 것이다. (A)는 조생종이고, (B)는 만생종이며, (C)는 한초 품종의 산초이다. 시료 1, 4 및 7은 유압압착으로 착유한 것으로, 껍질이 10% 포함된 것이며; 시료 2, 5 및 8은 유압압착으로 착유한 것으로, 껍질이 포함되지 않은 것이고; 시료 3, 6 및 9는 엑스펠라 착유한 것으로, 껍질이 포함되지 않은 것이다.Figure 2 shows the change in the expression level of inflammatory cytokines (IL-33) in A549 cells treated with varietal colostrum by varieties and milking methods. (A) is an early species, (B) is an endemic species, and (C) is an herbaceous variety of the herbaceous variety. Samples 1, 4 and 7 were milked by hydraulic compression, containing 10% shell; Samples 2, 5, and 8 were milked by hydraulic pressing, without shells; Samples 3, 6, and 9 were milked with Xpella and did not contain shells.
도 3은 품종 및 착유법별 산초유를 처리한 A549 세포에서의 염증성 사이토카인(IL-5)의 발현량 변화를 확인한 것이다. (A)는 조생종이고, (B)는 만생종이며, (C)는 한초 품종의 산초이다. 시료 1, 4 및 7은 유압압착으로 착유한 것으로, 껍질이 10% 포함된 것이며; 시료 2, 5 및 8은 유압압착으로 착유한 것으로, 껍질이 포함되지 않은 것이고; 시료 3, 6 및 9는 엑스펠라 착유한 것으로, 껍질이 포함되지 않은 것이다.Figure 3 shows the change in the expression level of inflammatory cytokines (IL-5) in A549 cells treated with varietal colostrum by varieties and milking methods. (A) is an early species, (B) is an endemic species, and (C) is an herbaceous variety of the herbaceous variety. Samples 1, 4 and 7 were milked by hydraulic compression, containing 10% shell; Samples 2, 5, and 8 were milked by hydraulic pressing, without shells; Samples 3, 6, and 9 were milked with Xpella and did not contain shells.
도 4는 품종 및 착유법별 산초유를 처리한 A549 세포에서의 염증성 사이토카인(TSLP; thymic stromal lymphopoietin)의 발현량 변화를 확인한 것이다. (A)는 조생종이고, (B)는 만생종이며, (C)는 한초 품종의 산초이다. 시료 1, 4 및 7은 유압압착으로 착유한 것으로, 껍질이 10% 포함된 것이며; 시료 2, 5 및 8은 유압압착으로 착유한 것으로, 껍질이 포함되지 않은 것이고; 시료 3, 6 및 9는 엑스펠라 착유한 것으로, 껍질이 포함되지 않은 것이다.Figure 4 shows the change in the expression level of inflammatory cytokines (TSLP; thymic stromal lymphopoietin) in A549 cells treated with varieties and milking method. (A) is an early species, (B) is an endemic species, and (C) is an herbaceous variety of the herbaceous variety. Samples 1, 4 and 7 were milked by hydraulic compression, containing 10% shell; Samples 2, 5, and 8 were milked by hydraulic pressing, without shells; Samples 3, 6, and 9 were milked with Xpella and did not contain shells.
도 5는 착유법별 한초 품종의 산초유를 처리한 원발성 기관지 상피 세포(primary tracheal epithelial cells) 세포에서의 염증성 사이토카인(IL-25, IL-33, IL-5, TSLP)의 발현량 변화를 확인한 것이다. 시료 7은 유압압착으로 착유한 것으로, 껍질이 10% 포함된 것이며; 시료 8은 유압압착으로 착유한 것으로, 껍질이 포함되지 않은 것이고; 시료 9는 엑스펠라 착유한 것으로, 껍질이 포함되지 않은 것이다.Figure 5 shows the changes in the expression level of inflammatory cytokines (IL-25, IL-33, IL-5, TSLP) in primary tracheal epithelial cells treated with acetic acid of Hancho variety by milking method will be. Sample 7 was milked by hydraulic compression, containing 10% shell; Sample 8 was milked by hydraulic pressing, without shells; Sample 9 was milked with xpella and does not contain shells.
도 6은 천식 유도 동물모델 확립 및 본 발명에 따른 산초유의 효능을 확인하기 위한 프로토콜을 나타낸 것이다.6 shows a protocol for establishing an asthma-induced animal model and confirming the efficacy of colostrum according to the present invention.
도 7은 본 발명에 따른 한초 품종의 산초유를 투여한 천식 유도 동물 모델의 기관지 폐포 세척액(BAL fluids)에서 염증 세포를 분석한 결과이다.Figure 7 is a result of analyzing the inflammatory cells in the bronchial alveolar lavage fluid (BAL fluids) of the asthma-induced animal model to which the acetic acid of the herb varieties according to the present invention.
도 8은 본 발명에 따른 한초 품종의 산초유를 투여한 천식 유도 동물 모델의 폐 조직에서의 사이토카인(IL-4 및 IL-13)의 발현량 변화를 확인한 웨스턴 블랏 결과이다.8 is a Western blot result confirming the expression changes of cytokines (IL-4 and IL-13) in the lung tissue of an asthma-derived animal model to which the herbal herb of the herb varieties according to the present invention was administered.
도 9는 본 발명에 따른 한초 품종의 산초유를 투여한 천식 유도 동물모델의 기도 과민성 변화를 분석한 결과이다.9 is a result of analyzing the changes in airway hypersensitivity in the asthma-induced animal model to which the administration of the herbal herb of Hancho variety according to the present invention.
도 10은 본 발명에 따른 한초 품종의 산초유를 투여한 천식 유도 동물모델의 폐 조직의 형태학적 분석결과이다.10 is a result of morphological analysis of lung tissue of an asthma-induced animal model to which the acetic acid of Hancho variety according to the present invention was administered.
본 발명은 엑스펠라(Ex pela)법으로 착유된 산초유를 유효성분으로 함유하는 염증성 질환의 예방 또는 개선용 건강기능식품 조성물에 관한 것이다.The present invention relates to a nutraceutical composition for the prevention or improvement of inflammatory diseases containing acid colostrum milked by the Expela method as an active ingredient.
상기 산초유는 한초 품종의 산초유인 것이 특징이며, 한초10호, 한초5호, 한초15호 및 한초930호 중에서 선택된 하나 이상인 것이 바람직하지만 이에 한정하지 않는다. The sancho oil is characterized in that the varieties of hancho varieties, and preferably at least one selected from No. 10, No. 5, No. 15 and No. 930, but not limited thereto.
상기 염증성 질환은 염증반응을 유발하는 사이토카인 분비가 증가하여 발생되는 질환으로, 구체적으로는 천식, 기관지염, 만성폐쇄성폐질환, 아토피성 피부염, 알레르기, 전신성 홍반성 루푸스, 경피증, 궤양성 대장염, 크론병, 건선, 아나필락시스, 피부염, 당뇨병성 망막증, 망막염, 황반 변성, 포도막염, 결막염, 관절염, 류마티스성 관절염, 강직성 척추염, 골관절염, 골다공증, 당뇨, 당뇨성 신장병, 신염, 신장염, 쇼그렌 증후군, 크론씨 병, 자가 면역 췌장염, 치주질환, 이식편 대 숙주 질환, 만성 골반 염증 질환, 자궁내막염, 비염, 편도염, 중이염, 인후염, 방광염 및 만성 전립선염 중에서 하나 이상인 것이 바람직하며, 더 바람직하게는 천식, 알레르기성 염증 또는 아토피 피부염이지만 이에 제한하는 것은 아니다. The inflammatory disease is a disease caused by increased cytokine secretion causing an inflammatory response, specifically, asthma, bronchitis, chronic obstructive pulmonary disease, atopic dermatitis, allergy, systemic lupus erythematosus, scleroderma, ulcerative colitis, Crohn Disease, psoriasis, anaphylaxis, dermatitis, diabetic retinopathy, retinitis, macular degeneration, uveitis, conjunctivitis, arthritis, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, osteoporosis, diabetes, diabetic nephropathy, nephritis, nephritis, Sjogren's syndrome, Crohn's disease, Autoimmune pancreatitis, periodontal disease, graft-versus-host disease, chronic pelvic inflammatory disease, endometritis, rhinitis, tonsillitis, otitis media, sore throat, cystitis and chronic prostatitis, more preferably asthma, allergic inflammation or Atopic dermatitis, but not limited to.
본 발명의 건강기능식품 조성물은 분말, 과립, 환, 정제, 캡슐, 캔디, 시럽 및 음료 중에서 선택된 어느 하나의 제형으로 제조될 수 있으며, 이에 한정하지 않는다.The dietary supplement composition of the present invention may be prepared in any one formulation selected from powders, granules, pills, tablets, capsules, candy, syrups and beverages, but is not limited thereto.
본 발명의 건강기능식품 조성물을 식품첨가물로 사용하는 경우, 상기 건강기능식품 조성물을 그대로 첨가하거나 다른 식품 또는 식품성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분은 그의 사용 목적(예방 또는 개선)에 따라 적절하게 사용될 수 있다. 일반적으로, 식품 또는 음료의 제조시 본 발명의 건강기능식품 조성물은 원료에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양으로 첨가된다. 그러나 건강을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로 사용될 수 있다.When the health functional food composition of the present invention is used as a food additive, the health functional food composition may be added as it is or used with other foods or food ingredients, and may be appropriately used according to a conventional method. The active ingredient may be appropriately used depending on the purpose of use (prevention or improvement). In general, in the preparation of food or beverages, the nutraceutical composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less based on the raw materials. However, in the case of long-term intake for health purposes, the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.
상기 건강기능식품의 종류에 특별한 제한은 없다. 상기 건강기능식품 조성물을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the type of dietary supplement. Examples of foods to which the health functional food composition may be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products, including ice cream, various soups, drinks, tea Drinks, alcoholic beverages, vitamin complexes, and the like, and include all health foods in the conventional sense.
또한, 본 발명의 건강기능식품 조성물은 식품, 특히 기능성 식품으로 제조될 수 있다. 본 발명의 기능성 식품은 통상적으로 첨가되는 성분을 포함할 수 있다. 예를 들어, 단백질, 탄수화물, 지방, 영양소 및 조미제를 포함한다. 예컨대, 드링크제로 제조되는 경우에는 유효성분 이외에 천연 탄수화물 또는 향미제를 추가 성분으로서 포함시킬 수 있다. 상기 천연 탄수화물은 모노사카라이드(예컨대, 글루코오스, 프럭토오스 등), 디사카라이드(예컨대, 말토스, 수크로오스 등), 올리고당, 폴리사카라이드(예컨대, 덱스트린, 시클로덱스트린 등) 또는 당알코올(예컨대, 자일리톨, 소르비톨, 에리쓰리톨 등)인 것이 바람직하다. 상기 향미제는 천연 향미제(예컨대, 타우마틴, 스테비아 추출물 등)와 합성 향미제(예컨대, 사카린, 아스파르탐 등)를 이용할 수 있다.In addition, the nutraceutical composition of the present invention may be prepared as a food, in particular a functional food. The functional food of the present invention may include ingredients that are commonly added. Examples include proteins, carbohydrates, fats, nutrients and seasonings. For example, when prepared with a drink, natural carbohydrates or flavors may be included as additional ingredients in addition to the active ingredient. The natural carbohydrates can be monosaccharides (e.g. glucose, fructose, etc.), disaccharides (e.g. maltose, sucrose, etc.), oligosaccharides, polysaccharides (e.g. dextrins, cyclodextrins, etc.) or sugar alcohols (e.g. , Xylitol, sorbitol, erythritol and the like). The flavourant may be a natural flavourant (eg, taumartin, stevia extract, etc.) and a synthetic flavourant (eg, saccharin, aspartame, etc.).
상기 건강기능식품 조성물 이외에 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 더 함유할 수 있다. 이러한 상기 첨가되는 성분의 비율은 크게 중요하진 않지만 본 발명의 건강기능식품 조성물 100 중량부에 대하여, 0.01 내지 0.1 중량부의 범위에서 선택되는 것이 일반적이다.Various nutritional supplements, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, carbonic acid The carbonation agent etc. which are used for a drink can be contained further. Although the ratio of the above-mentioned ingredients is not critical, it is generally selected from 0.01 to 0.1 parts by weight based on 100 parts by weight of the health functional food composition of the present invention.
또한, 본 발명은 엑스펠라(Ex pela)법으로 착유된 산초유를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학 조성물에 관한 것이다.The present invention also relates to a pharmaceutical composition for the prevention or treatment of inflammatory diseases containing acid colostrum milked by the Expela method as an active ingredient.
상기 산초유는 한초 품종의 산초유인 것이 특징이며, 한초10호, 한초5호, 한초15호 및 한초930호 중에서 선택된 하나 이상인 것이 바람직하지만 이에 한정하지 않는다. The sancho oil is characterized in that the varieties of hancho varieties, and preferably at least one selected from No. 10, No. 5, No. 15 and No. 930, but not limited thereto.
본 발명에 따른 산초유을 포함하는 약학조성물은 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플라스마제의 제형인 것이 바람직하지만 이에 한정하지 않는다. The pharmaceutical composition comprising the acidic colostrum according to the present invention is preferably a formulation of a cream, gel, patch, spray, ointment, warning, lotion, linen, pasta or cataplasma, but is not limited thereto.
상기 산초유 이외에 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 더 포함할 수 있으며, 산초유을 포함하는 약학 조성물에 포함될 수 있는 담체, 부형제 또는 희석제로는 락토즈, 덱스트로즈, 수크로스, 올리고당, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다.A carrier, excipient or diluent, which may be included in the pharmaceutical composition including acid colostrum, may further include a pharmaceutically acceptable carrier, excipient or diluent in addition to the acid colostrum, and lactose, dextrose, sucrose, oligosaccharide, Sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydride Oxybenzoate, talc, magnesium stearate and mineral oil. When formulated, it may be prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc. which are commonly used.
본 발명의 산초유의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 본 발명의 산초유을 포함하는 약학조성물은 1일 0.0001 내지 100㎎/㎏으로, 바람직하게는 0.001 내지 10㎎/㎏으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.Preferred dosages of the colostrum of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the desired effect, the pharmaceutical composition containing the acidic oil of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably 0.001 to 10 mg / kg per day. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
또한, 본 발명은 엑스펠라(Ex pela)법으로 착유된 산초유를 유효성분으로 함유하는 천식 또는 아토피 피부염 개선용 의약외품에 관한 것이다.The present invention also relates to quasi-drugs for improving asthma or atopic dermatitis containing acid colostrum milked by the Expela method as an active ingredient.
상기 의약외품은 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액, 파운데이션, 왁스 파운데이션 및 스프레이 중에서 선택된 어느 하나의 제형으로 제조되는 것이 바람직하지만 이에 한정하는 것은 아니다.The quasi-drug is prepared in any one formulation selected from solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsions, foundations, wax foundations and sprays. It is preferable, but it is not limited to this.
이하, 실시예를 이용하여 본 발명을 더욱 상세하게 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로 본 발명의 범위가 이들에 의해 제한되지 않는다는 것은 당해 기술분야에서 통상의 지식을 가진 자에게 있어 자명한 것이다. Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for explaining the present invention in more detail, it is obvious to those skilled in the art that the scope of the present invention is not limited by them.
실시예Example
1. One.
in vitroin vitro
염증성 사이토카인의 발현량 변화 분석 Analysis of Changes in Inflammatory Cytokine Expression
원발성 기관지 상피 세포(primary tracheal epithelial cells)와 A549 세포에, DMSO로 10배 희석한 산초유 시료를 최종 0.01%(v/v)이 되도록 처리하고, 1시간 후, 50ng/㎖의 TNF-α 및 100㎍/㎖의 LPS로 11시간 동안 자극하였다. 산초유 처리 후, 12시간째에 분해완충액(lysis buffer)으로 세포 분해물을 획득하여 브래드포드법으로 단백질을 정량하고, 웨스턴 블랏을 수행하여 단백질의 발현량 변화를 확인하였다. Primary tracheal epithelial cells and A549 cells were treated with a sample of colostrum diluted 10-fold with DMSO to 0.01% (v / v) final, and after 1 hour, 50ng / ml of TNF-α and Stimulation was performed with 100 μg / ml of LPS for 11 hours. After 12 hours of treatment with acetic acid, cell lysates were obtained by lysis buffer, protein was quantified by Bradford method, and Western blot was performed to confirm changes in expression levels of proteins.
본 발명의 실시예에서는 3가지 품종인 조생종, 만생종 및 한초 산수유 품종에 대하여, 유압압착 또는 엑스펠라 착유를 통해 획득한 9가지 경우에 대한 시료에 대하여 염증성 사이토카인(IL-25, IL-33, IL-5 및 TSLP)의 발현량 변화를 분석하였다. In the embodiment of the present invention, the three cultivars of crude, late and varieties of horticulture, inflammatory cytokines (IL-25, IL-33, against the samples for nine cases obtained through hydraulic compression or expeller milking) IL-5 and TSLP) expression level changes were analyzed.
[시험군][Test group]
시료 1: 조생종+유압압착 (껍질 10% 포함)Sample 1: crude species + hydraulic press (with 10% shell)
시료 2: 조생종+유압압착 (껍질 불포함)Sample 2: Crude + Hydraulic Press (no shell)
시료 3: 조생종+엑스펠라 착유 (껍질 불포함)Sample 3: Crude + Expella Milking (without Shell)
시료 4: 만생종+유압압착 (껍질 10% 포함)Sample 4: live species + hydraulic press (with 10% shell)
시료 5: 만생종+유압압착 (껍질 불포함)Sample 5: All Species + Hydraulic Press (Skin Not Included)
시료 6: 만생종+엑스펠라 착유 (껍질 불포함)Sample 6: All-breed + Expella Milking (without Shell)
시료 7: 한초+유압압착 (껍질 10% 포함)Sample 7: vinegar + hydraulic press (with 10% shell)
시료 8: 한초+유압압착 (껍질 불포함)Sample 8: Herbal + Hydraulic Press (no shell)
시료 9: 한초+엑스펠라 착유 (껍질 불포함)Sample 9: milkweed + xpella milking (no shell)
그 결과, 도 1 내지 도 4에 개시한 바와 같이, LPS에 의해 자극된 A549 세포에서 산초유의 추출방법에 따른 효능을 보았을 때, LPS에 의해 자극된 A549 세포의 결과 분석에서 유압압착 방식보다 엑스펠라 착유시, LPS에 의해 자극된 A549 세포에서 증가된 염증 사이토카인(IL-25, IL-33, IL-5 및 TSLP) 발현을 감소시켰으며, 그 중에서도 한초 품종의 효능이 현저하게 나타났다. As a result, as shown in Figs. 1 to 4, when seeing the efficacy according to the method of extracting the colostrum in the A549 cells stimulated by LPS, in the analysis of the results of A549 cells stimulated by LPS in the analysis of the extruder than the hydraulic compression method At the time of milking, increased inflammatory cytokines (IL-25, IL-33, IL-5 and TSLP) expression was reduced in A549 cells stimulated by LPS, among which the efficacy of Hancho variety was remarkable.
또한, 상기 LPS에 의해 자극된 A549 세포에서의 결과를 기반으로, LPS에 의해 자극된 원발성 기관지 상피 세포(primary tracheal epithelial cells)에서의 한초 품종에 대한 염증성 사이토카인의 발현량 변화를 재확인한 결과, 한초의 엑스펠라 착유시료에서, LPS에 의해 자극된 원발성 기관지 상피 세포(primary tracheal epithelial cells)에서 증가된 사이토카인의 발현량이 감소하는 것을 확인하였다(도 5).In addition, based on the results in the A549 cells stimulated by the LPS, as a result of reconfirming the change in the expression level of inflammatory cytokines for Hancho variety in primary tracheal epithelial cells stimulated by LPS, It was confirmed that the expression level of increased cytokines in primary tracheal epithelial cells stimulated by LPS was reduced in the expeller milking samples.
실시예Example
2. 천식 마우스 모델에서의 2. Asthma in Mouse Model
산초유Sancho Milk
효능 확인 Efficacy Check
실시예 1의 결과를 기반으로, 본 발명의 엑스펠라 착유법으로 착유된 한초 품종을 OVA(ovalbumin)로 유도된 천식 마우스 모델에 경구투여하여 염증 세포 수, 염증에 관여하는 단백질 발현, 기도 과민반응 및 조직학적 분석을 실시하였다.Based on the results of Example 1, the herbaceous cultivars milked with the Expel milking method of the present invention were orally administered to an OVA (ovalbumin) -induced asthma mouse model, and the number of inflammatory cells, expression of proteins involved in inflammation, and airway hypersensitivity. And histological analysis.
[실험동물][Experimental animal]
동물은 C57BL/6 계통의 6주령 된 암컷 마우스를 Orientbio Inc.(성남, 한국)에서 구입하여 실험을 수행하였다. 천식 마우스모델 유도를 위해 saline에 10㎍/mouse의 OVA(ovalbumin)와 1mg의 Alum을 총 200㎕의 부피가 되도록 혼합하여, 0일과 14일에 복강투여로 감작시켰다. 첫 번째 감작 후, 21일, 22일, 23일째에 saline에 3% OVA(weight/volume)를 초음파 분무기를 이용하여 30분간 흡입시켰다 (Challenge). Animals were purchased from Orientbio Inc. (Seongnam, Korea) for 6 week-old female mice of C57BL / 6 strain. To induce an asthma mouse model, 10 μg / mouse OVA (ovalbumin) and 1 mg of Alum were mixed in a total volume of 200 μl in saline, and sensitized by intraperitoneal administration on days 0 and 14. After the first sensitization, 3% OVA (weight / volume) in saline was inhaled for 30 minutes using an ultrasonic nebulizer on the 21st, 22nd and 23rd days.
산초유는 옥수수 오일(drug vehicle)을 넣어, 산초유 원액을 각 시료의 0.2%와 2%으로 희석하여 사용하였다. 옥수수 오일과 산초유는 마지막 3% OVA challenge 하기 1시간 전과, 마지막 3% OVA challenge 6시간 후에 경구 투여하였으며, 총 2회를 진행하였다. The raw colostrum was added corn oil (drug vehicle), and the crude colostrum was diluted to 0.2% and 2% of each sample. Corn oil and colostrum were orally administered 1 hour before the last 3% OVA challenge and 6 hours after the last 3% OVA challenge.
산초유의 효능을 확인하기 위해, 마우스는 마지막 OVA challenge 후, 48시간째에 마우스를 희생시켜 실험을 수행하였다. 마우스 모델군은 아무것도 처리하지 않은 음성대조군(SAL+VEH), ovalbumin을 처리한 OVA군 및 ovalbumin 처리 및 산초유(한초 0.2 또는 2%)으로 분류하였다(도 6).To confirm the efficacy of the colostrum, the mice were sacrificed at 48 hours after the last OVA challenge. The mouse model group was classified into the negative control group (SAL + VEH), the oVA group treated with ovalbumin, and the ovalbumin-treated and acid colostrum (0.2 or 2% per second) (FIG. 6).
(1)(One)
기관지 폐포 세척액(Bronchial alveolar lavage fluid (
BALBAL
fluids)에서 염증 세포 분석 inflammatory cell analysis in fluids
마우스를 경추 탈골법으로 희생을 시키고, 기관에 1㎖의 PBS를 넣어 폐를 세척하여, 기관지 폐포 세척액을 얻었다. 전체 세포 수는 NucleoCounter (ChemoMetec, Allerod, Denmark)를 이용하여 측정하였고, BAL 세포 도말은 cytospin(Thermo Eletronm Waltham, MA)으로 준비하였다. 세포 감별을 위해서 Diff-Quik solution(Dade diagnostics of P.R. Inc.Aguada, Puerto Rico)으로 염색 후, 400개의 세포를 세어 분석하였으며, 염증세포 분석에서 효능을 보이는 시료를 선별하였다.Mice were sacrificed by cervical dislocation, 1 ml of PBS was added to the trachea to wash the lungs, and bronchial alveolar lavage fluid was obtained. Total cell number was measured using NucleoCounter (ChemoMetec, Allerod, Denmark), and BAL cell smears were prepared with cytospin (Thermo Eletronm Waltham, Mass.). For cell differentiation, after staining with Diff-Quik solution (Dade diagnostics of P.R. Inc.Aguada, Puerto Rico), 400 cells were counted and analyzed, and samples showing efficacy in inflammatory cell analysis were selected.
그 결과, 도 7에 개시한 바와 같이 천식동물모델에서 총 세포 수, 호산구(eosinophil) 및 림프구(lymphocyte)를 포함한 염증 세포가 유의하게 증가하였으며, 한초 2%를 투여한 실험군에서 총 세포 수와 호산구의 세포 수가 감소하는 것을 확인하였다. As a result, as shown in FIG. 7, the total cell number, inflammatory cells including eosinophil and lymphocytes were significantly increased in the asthma model, and the total cell number and eosinophil in the experimental group administered 2% per second. It was confirmed that the cell number of was reduced.
(2)(2)
웨스턴Weston
블랏Blot
및 밀도 분석(And density analysis (
densitometrydensitometry
analysis) analysis)
염증세포 분석에서 선별된 시료의 마우스 폐 조직을 분해 완충액(lysis buffer)를 넣어 균질화를 시키고, 폐 조직의 단백질 분해물(lysates)를 획득하였다. 브래드포드 기법으로 단백질을 정량하여 전기영동, 멤브레인 트랜스퍼(transfer) 및 블로킹 과정을 거쳐, IL-4 및 IL-13 항체를 오버나잇(overnight)으로 인큐베이션(incubation)하였다. 다음날 블랏(blot)을 세척하고, 2차 항체를 반응시키고, ECL 반응을 시키고, LAS 장비를 이용하여 분석하였다. Mouse lung tissue of the sample selected in the inflammatory cell analysis was homogenized with lysis buffer to obtain protein lysates of lung tissue. Proteins were quantified by the Bradford technique, followed by electrophoresis, membrane transfer, and blocking to incubate IL-4 and IL-13 antibodies overnight. The next day the blots were washed, the secondary antibodies reacted, the ECL reactions were analyzed and analyzed using the LAS instrument.
그 결과, 천식동물모델의 폐 조직에서 IL-4 및 IL-13 단백질이 증가하였으며. 본 발명의 한초 품종의 산초유를 투여한 동물모델에서는 증가했던 IL-4 및 IL-13 단백질이 감소하는 것을 확인하였다(도 8).As a result, IL-4 and IL-13 proteins were increased in lung tissue of the asthma model. It was confirmed that the increased IL-4 and IL-13 protein was decreased in the animal model administered with the acetic acid of Hancho variety of the present invention (Fig. 8).
(3) 기도 저항성 측정 (3) airway resistance measurement
염증세포 분석에서 선별된 시료의 기도 과민성에 대한 효과를 평가하기 위하여 동물용 기도저항 측정기 Flexivent (Scientific Respiratory Equipment Inc., Montreal, Canada)을 이용하였다. 이는 Invasive method로 마우스의 마취상태에서, 메타콜린 (Methacholine) 농도(0, 5, 10, 25, 50 mg/㎖)의 변화에 따른 airway resistance (Rrs) 값을 측정하였다. 마우스는 메타콜린을 흡입시키기 전에 0.9% 생리식염수를 10초간 분무시켜 기저(Basal control) 기도 과민성을 측정하였고, 메타콜린에 대한 기도 반응의 차이를 확인하기 위하여 각 마우스에게 초음파분무기를 이용하여 메타콜린의 농도를 증가시키며 측정하였다. 각 농도의 메타콜린 투여 후, 3분간 Rrs 값을 측정하여 평균값을 사용하였다. 기도 기능의 변화 정도는 0.9% 생리식염수 흡입 후 얻어진 기저 Rrs 값을 기준으로 그 차이를 백분율로 표현하였다. In order to evaluate the effect on the airway hypersensitivity of selected samples in inflammatory cell analysis, animal airway resistance meter Flexivent (Scientific Respiratory Equipment Inc., Montreal, Canada) was used. This was measured by airway resistance (Rrs) according to the change of methacholine concentration (0, 5, 10, 25, 50 mg / ㎖) in anesthesia of the mouse by the Invasive method. Mice were sprayed with 0.9% physiological saline for 10 seconds prior to inhaling methacholine to measure basal control airway hypersensitivity, and each mouse was treated with methacholine using an ultrasonic nebulizer to determine the difference in airway response to methacholine. It was measured while increasing the concentration of. After administration of each concentration of methacholine, the Rrs value was measured for 3 minutes and the average value was used. The change in airway function was expressed as a percentage based on the basal Rrs value obtained after 0.9% saline inhalation.
기도과민성 분석 결과, 천식동물모델 군은 음성대조군(SAL+VEH)에 비해, 메타콜린의 농도 의존적으로 기도 과민성의 증가를 보였으며, 증가된 기도 과민성은 한초 2%를 투여한 실험군에서 감소되는 것을 확인하였다(도 9).As a result of airway hypersensitivity analysis, asthma model group showed increased airway hypersensitivity in a dose-dependent manner compared to negative control group (SAL + VEH), and increased airway hypersensitivity was decreased in the experimental group administered 2% per second. It was confirmed (FIG. 9).
(4)(4)
조직학적 분석Histological analysis
염증세포 분석에서 선별된 시료의 조직학적 분석을 하기 위해, 마지막 OVA challenge 후 48시간째에 마우스에서 폐 조직을 떼어내어, 4% 포르말린에 고정시켰다. 검체를 탈수시키고, 파라핀으로 고정하여, Leica model 2165 rotary microtome(Leica Microsystems NusslochGmbH, Nussloch, Germany) 장비로 4μm의 절편으로 슬라이드에 붙였다. 조직은 다시 탈 파라핀 과정과 함수과정을 거쳐 H&E 염색하였고, 조직학적으로 폐의 염증 정도를 평가하기 위해 염증(inflammatory) score를 분석하였다For histological analysis of selected samples in inflammatory cell assay, lung tissue was removed from mice 48 hours after the last OVA challenge and fixed in 4% formalin. Samples were dehydrated and fixed with paraffin and attached to slides in 4 μm sections with a Leica model 2165 rotary microtome (Leica Microsystems Nussloch GmbH, Nussloch, Germany). The tissues were then deparaffinized and hydrolyzed and H & E stained. Histologically, the inflammatory scores were analyzed to evaluate lung inflammation.
그 결과, 천식동물모델의 병리조직 검사에서 상피세포층이 두꺼워졌으며 기관지와 혈관 주위에 염증세포의 침윤의 증가가 유의하게 나타났으며, 한초 2%를 처리한 실험군에서 병리적 변화가 유의하게 호전되는 것을 관찰할 수 있었다(도 10).As a result, the pathological examination of the asthma model showed a thickening of the epithelial cell layer, a significant increase in inflammatory cell infiltration around the bronchus and blood vessels, and significantly improved pathological changes in the experimental group treated with 2% per second. It could be observed (Fig. 10).
[통계 처리][Statistical processing]
모든 결과는 평균과 표준 오차로 표시하였다. 통계분석은 정규성 검증 후, 정규성 검증에 따르면, one-way ANOVA를 이용하여 scheffe's 사후 검증을 진행하였고, p<0.05인 경우를 통계적 의의가 있는 것으로 해석하였다. 정규성 검증에 따르지 않으면, Kruskal-Wallis ANOVA test 후, Mann Whitney U test를 진행하였다.All results are expressed as mean and standard error. In the statistical analysis, after the normality test, according to the normality test, scheffe's post-test was conducted by using one-way ANOVA, and p <0.05 was interpreted as statistically significant. If the test was not followed, the Kruskal-Wallis ANOVA test was followed by the Mann Whitney U test.
Claims (7)
- 엑스펠라(Ex pela)법으로 착유된 산초유를 유효성분으로 함유하는 염증성 질환의 예방 또는 개선용 건강기능식품 조성물.Health functional food composition for the prevention or improvement of inflammatory diseases containing acid colostrum milked by the Expela method as an active ingredient.
- 제1항에 있어서, 상기 산초유는 한초 품종의 산초유인 것을 특징으로 하는 염증성 질환의 예방 또는 개선용 건강기능식품 조성물.The health functional food composition for preventing or ameliorating an inflammatory disease according to claim 1, wherein the sancho oil is a sancho milk of Hancho variety.
- 제1항에 있어서, 상기 염증성 질환은 천식, 기관지염, 만성폐쇄성폐질환, 아토피성 피부염, 알레르기, 전신성 홍반성 루푸스, 경피증, 궤양성 대장염, 크론병, 건선, 아나필락시스, 피부염, 당뇨병성 망막증, 망막염, 황반 변성, 포도막염, 결막염, 관절염, 류마티스성 관절염, 강직성 척추염, 골관절염, 골다공증, 당뇨, 당뇨성 신장병, 신염, 신장염, 쇼그렌 증후군, 크론씨 병, 자가 면역 췌장염, 치주질환, 이식편 대 숙주 질환, 만성 골반 염증 질환, 자궁내막염, 비염, 편도염, 중이염, 인후염, 방광염 및 만성 전립선염 중에서 선택된 하나 이상인 것을 특징으로 하는 염증성 질환의 예방 또는 개선용 건강기능식품 조성물.The method of claim 1, wherein the inflammatory disease is asthma, bronchitis, chronic obstructive pulmonary disease, atopic dermatitis, allergy, systemic lupus erythematosus, scleroderma, ulcerative colitis, Crohn's disease, psoriasis, anaphylaxis, dermatitis, diabetic retinopathy, retinitis Macular degeneration, uveitis, conjunctivitis, arthritis, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, osteoporosis, diabetes, diabetic nephropathy, nephritis, nephritis, Sjogren's syndrome, Crohn's disease, autoimmune pancreatitis, periodontal disease, graft-versus-host disease, chronic Health functional food composition for the prevention or improvement of inflammatory diseases, characterized in that the pelvic inflammatory disease, endometritis, rhinitis, tonsillitis, otitis media, sore throat, cystitis and chronic prostatitis.
- 제1항에 있어서, 상기 조성물은 분말, 과립, 환, 정제, 캡슐, 캔디, 시럽 및 음료 중에서 선택된 어느 하나의 제형으로 제조되는 것을 특징으로 하는 염증성 질환의 예방 또는 개선용 건강기능식품 조성물.According to claim 1, wherein the composition is a health functional food composition for the prevention or improvement of inflammatory diseases, characterized in that the formulation is made of any one selected from powders, granules, pills, tablets, capsules, candy, syrups and beverages.
- 엑스펠라(Ex pela)법으로 착유된 산초유를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학 조성물.Pharmaceutical composition for the prevention or treatment of inflammatory diseases containing acid colostrum milked by the Expela method as an active ingredient.
- 엑스펠라(Ex pela)법으로 착유된 산초유를 유효성분으로 함유하는 천식 또는 아토피 피부염 개선용 의약외품.A quasi-drug for improving asthma or atopic dermatitis, which contains acid colostrum milked by the Expela method as an active ingredient.
- 제6항에 있어서, 상기 피부 외용제는 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액, 파운데이션, 왁스 파운데이션 및 스프레이 중에서 선택된 어느 하나의 제형으로 제조되는 것을 특징으로 하는 천식 또는 아토피 피부염 개선용 의약외품.The method of claim 6, wherein the skin external preparation is in solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion, foundation, wax foundation, and spray A quasi-drug for improving asthma or atopic dermatitis, which is prepared by any one of the selected dosage forms.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0034420 | 2018-03-26 | ||
KR1020180034420A KR102119855B1 (en) | 2018-03-26 | 2018-03-26 | Composition for preventing, ameliorating or treating inflammatory disease comprising Zanthoxylum schihifolium oil as effective component |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019189992A1 true WO2019189992A1 (en) | 2019-10-03 |
Family
ID=68062256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/005432 WO2019189992A1 (en) | 2018-03-26 | 2018-05-11 | Composition for preventing, alleviating or treating inflammatory diseases, containing zanthoxylum schinifolium oil as active ingredient |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102119855B1 (en) |
WO (1) | WO2019189992A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110892976A (en) * | 2019-12-16 | 2020-03-20 | 中国标准化研究院 | Hemp flavor extract and preparation method thereof |
CN112574834A (en) * | 2020-12-23 | 2021-03-30 | 山东农业大学 | Sterilizing and inflammation-diminishing soap and preparation method thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230122277A (en) | 2022-02-14 | 2023-08-22 | 정직한화장품 협동조합 | Massage cream composition and manufacturing method using sancho |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100042819A (en) * | 2008-10-17 | 2010-04-27 | 한국국제대학교 산학협력단 | Cosmetic composition comprising oil of zanthoxylum schinifolium for treatment of atopic dermatitis |
KR20130069982A (en) * | 2011-12-19 | 2013-06-27 | 덕성여자대학교 산학협력단 | Composition for prevention or treatment of osteoporosis comprising essential oil of zanthoxylum schinifolium |
-
2018
- 2018-03-26 KR KR1020180034420A patent/KR102119855B1/en active IP Right Grant
- 2018-05-11 WO PCT/KR2018/005432 patent/WO2019189992A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100042819A (en) * | 2008-10-17 | 2010-04-27 | 한국국제대학교 산학협력단 | Cosmetic composition comprising oil of zanthoxylum schinifolium for treatment of atopic dermatitis |
KR20130069982A (en) * | 2011-12-19 | 2013-06-27 | 덕성여자대학교 산학협력단 | Composition for prevention or treatment of osteoporosis comprising essential oil of zanthoxylum schinifolium |
Non-Patent Citations (5)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110892976A (en) * | 2019-12-16 | 2020-03-20 | 中国标准化研究院 | Hemp flavor extract and preparation method thereof |
CN112574834A (en) * | 2020-12-23 | 2021-03-30 | 山东农业大学 | Sterilizing and inflammation-diminishing soap and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
KR102119855B1 (en) | 2020-06-05 |
KR20190112431A (en) | 2019-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2606768C1 (en) | Purified extract separated from pseudolysimachion rotundum var subintegrum with high content of active ingredient, its production and composition containing the above extract as an active ingredient to prevent or treat inflammation, allergies and asthma | |
EP3132799B1 (en) | Pharmaceutical composition comprising pistacia weinmannifolia extract, fraction of same or compound separated from same for preventing or treating chronic obstructive pulmonary disease (copd) | |
WO2019189992A1 (en) | Composition for preventing, alleviating or treating inflammatory diseases, containing zanthoxylum schinifolium oil as active ingredient | |
EP3991742A1 (en) | Coronavirus therapeutic agent comprising elaeocarpus sylvestris extract as active ingredient | |
CN113350439B (en) | Application of traditional Chinese medicine composition in preparation of antiviral drugs | |
US11135193B2 (en) | Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma | |
EP3025721B1 (en) | Pharmaceutical composition for preventing or treating asthma comprising pistacia weinmannifolia j. poiss. ex franch extract or fraction thereof | |
EP3189846A1 (en) | Pharmaceutical composition for prevention or treatment neuro-inflammation or neurodegenerative diseases comprising Portulaca grandiflora Hook. extracts or fractions thereof | |
WO2022124803A1 (en) | Composition for preventing, alleviating, or treating allergic diseases, comprising extract of spatholobus suberectus as active ingredient | |
WO2020122373A1 (en) | Composition comprising glycyrrhiza uralensis extract as active ingredient for prevention, alleviation, or treatment of late-onset hypogonadism syndrome | |
WO2023121334A1 (en) | Composition comprising cardamine flexuosa extract as active ingredient for prevention, alleviation, or treatment of respiratory disease | |
KR20220077317A (en) | Composition for preventing and improving viral diseases | |
WO2023121331A1 (en) | Composition for prevention, amelioration or treatment of respiratory disease containing lysimachia mauritiana extract as active ingredient | |
KR101906208B1 (en) | Pharmaceutical Composition for preventing or treating constipation comprising Liriope platyphylla extract, Glycyrrhiza uralensis Fischer and Chinese Liquorice as an active ingredient | |
WO2018186705A1 (en) | Composition, containing siraitia grosvenorii residue extract as active ingredient, for prevention, alleviation, or treatment of inflammation | |
WO2020027574A1 (en) | Composition for preventing, alleviating or treating respiratory diseases, containing siraitia grosvenorii extract as active ingredient | |
WO2012067322A1 (en) | Pharmaceutical composition for treatment of asthma containing 4-phenylbutyric acids or pharmaceutically acceptable salts thereof as active ingredient | |
WO2017142255A1 (en) | Composition containing medicinal herb extract as active ingredient for preventing, alleviating, or treating stress or depression | |
KR20200035785A (en) | Composition for Enhancing Immunity comprising Agastachis Herba Extract as effective component | |
WO2021172726A1 (en) | Health functional food composition containing extract of sanguisorba officinalis l. | |
WO2023287151A1 (en) | Composition for preventing, alleviating, or treating respiratory diseases, comprising fermented centella asiatica extract as active ingredient | |
KR102716093B1 (en) | Composition for preventing or treating inflammatory lung diseases comprising Prasiola japonica extract or fraction thereof as active ingredient | |
KR102410055B1 (en) | Composition for treating, alleviating or preventing respiratory inflammatory disease | |
WO2022131776A1 (en) | Composition for preventing or treating colitis, comprising pyrus ussuriensis extract or pyrus ussuriensis fermentation product as active ingredient | |
WO2023195644A1 (en) | Composition for prevention, amelioration or treatment of asthma containing malus baccata var. mandshurica extract as active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18911905 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18911905 Country of ref document: EP Kind code of ref document: A1 |